welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Capricor receives rare pediatric disease designation for DMD drug
The U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation to CAP-1002 to treat Duchenne muscular dystrophy (DMD).
If approved, CAP-1002 manufacturer, Capricor Therapeutics would receive a Priority Review Voucher which can be worth millions of dollars.
DMD is a rare genetic disorder that results in progressive degeneration and muscle due to disruption of the dystrophin protein complex in muscle tissue. DMD patients typically lose the ability to walk between the ages of 10 to 12 and typically die in their 20’s of heart failure. There approximately 15,000 to 20,000 affected people in the U.S
rareRelated
-
Capricor places Duchenne drug trial on holdCapricor Therapeutics Inc said on Wednes...
-
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDACapricor Therapeutics, a clinical-stag...
-
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystr...Capricor Therapeutics, Inc., a biotechno...
-
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)HOPE-2 is a double-blind clinical trial ...
-
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical TrialCapricor Therapeutics announced today th...
-
HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)Male subjects with cardiomyopathy second...
-
Capricor trial failure in heart disease might offer another opportunityOn Friday Capricor Therapeutics announce...